Masonic Cancer Center, University of Minnesota: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials

The registry lists 28 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 5 are open to participants now and 13 have results posted.

Phase 1 6Phase 2 19Phase 3 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
• MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
• Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through ExerciseRecruitingNCT05025774
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
• Auto Stem Cell Transplant for Lymphoma PatientsRecruitingNCT03125642Phase 2
• Trial Evaluating MGTA-456 in Patients With High-Risk MalignancyActive, not recruitingNCT03674411Phase 2Results posted
• MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingNCT03642626Phase 2Results posted
• Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTCompletedNCT01885897Phase 1/2Results posted
• Busulfan and Cyclophosphamide Followed By ALLO BMTTerminatedNCT01685411Not applicableResults posted
• Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01312818Phase 2Results posted
• Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00882206Phase 2Results posted
• Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
• Study of Immune Response Modifier in the Treatment of Hematologic MalignanciesTerminatedNCT00276159Phase 2Results posted
• Stem Cell Transplant for Hematological MalignancyTerminatedNCT00176930Not applicableResults posted
• Stem Cell Transplantation for Hematological MalignanciesTerminatedNCT00176839Phase 2/3Results posted
• Post Transplant Donor Lymphocyte InfusionTerminatedNCT00167180Phase 2Results posted
• StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme MalignanciesWithdrawnNCT02765997Phase 2
• Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
• Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
• Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute LeukemiaWithdrawnNCT01677949Phase 2
• Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
• AHN-12 Biodistribution in Advanced LeukemiaTerminatedNCT01207076Phase 1
• T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
• Total Marrow Irradiation for Refractory Acute LeukemiaCompletedNCT00686556Phase 1
• Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic LeukemiaTerminatedNCT00643240Phase 1
• Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) LeukemiaCompletedNCT00167167Not applicable